Treatment with semaglutide 2.4 mg also significantly improved symptoms, evaluated with the Kansas City Cardiomiopathy Questionnaire, and physical limitations, evaluated with the 6 min walking test, in the STEP-HFpEF trial, enrolling 529 patients with obesity and HF with preserved ejection fraction 89
Supporting strategies: Rigorous sleep hygiene despite frustration with results
What the animal data cannot tell us is what happens in humans
Start with 0.5-1mg daily if injecting, or a 1-2% topical product applied once daily
There is no universally accepted standard, as clinical data on the combination is lacking
Int J Obes (Lond) 40(8):13101319 Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin A et al (2024) Tirzepatide for the treatment of obstructive sleep apnea and obesity